$96.1 Million is the total value of Stonepine Capital Management, LLC's 17 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 22.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | Sell | IVERIC BIO INC | $13,323,000 | -4.6% | 2,362,240 | -13.8% | 13.86% | -48.8% |
| CTIC | Sell | CTI BIOPHARMA CORP | $8,102,000 | +71.7% | 3,768,597 | -7.4% | 8.43% | -7.8% |
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $2,709,000 | +39.6% | 657,467 | -13.2% | 2.82% | -25.0% |
| APEN | Sell | APOLLO ENDOSURGERY INC | $2,409,000 | +1.8% | 1,425,435 | -1.5% | 2.51% | -45.3% |
| NEOS | Sell | NEOS THERAPEUTICS INC | $2,325,000 | -23.7% | 4,384,199 | -1.4% | 2.42% | -59.0% |
| CPIX | Sell | CUMBERLAND PHARMACEUTICALS | $1,892,000 | -16.0% | 589,497 | -12.9% | 1.97% | -54.9% |
| PROG | Sell | PROGENITY INC | $614,000 | -29.0% | 68,062 | -29.2% | 0.64% | -61.9% |
| BBI | Exit | BRICKELL BIOTECH INC | $0 | – | -146,739 | -100.0% | -0.28% | – |
| CERC | Exit | CERECOR INC | $0 | – | -450,500 | -100.0% | -2.27% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.